Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

Sponsor
Yonsei University
Study ID
NCT05665023
Phase
PHASE2
Status
Unknown

Conditions

  • Fallopian Tube Cancer
  • Mucinous Ovarian Cancer
  • Primary Peritoneal Cancer

Eligibility Criteria

Sex
FEMALE
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab + modified FOLFIRINOX — DRUG
    Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week

Study Details

This research study is evaluating a modified FOLFIRINOX plus bevacizumab therapy for mucinous ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Key Dates

First listed
Dec 27, 2022
Start date
Oct 28, 2022
Status verified
Dec 2022
Primary completion
Feb 1, 2024
Completion
Feb 1, 2025

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab + modified FOLFIRINOX
    Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week

Primary Outcome Measure

Objective response rate [ Time Frame: up to 1 year ]

Central Contacts

Related Studies